Clinical Evidence
Novaerus technology has been shown to safely and effectively reduce bacteria, viruses, VOCs, and particulate matter in dozens of independent laboratory tests. In case studies and clinical trials, Novaerus products have been demonstrated to reduce infections and improve well being in real-world settings.
Journal of Clinical and Experimental Cardiology
Infection Control Unit Suppresses Airborne Aerosols during Cardiac Stress Testing in an Outpatient Cardiology Clinic
Evaluation of the Novaerus Technology in Hospital Wards
Novaerus reduces staff sickness, ward odours, infections and antibiotic use. Wards with Novaerus have had no outbreaks of MRSA, C. diff, influenza, or norovirus since installation.
Evaluation of the Novaerus Technology in a Hospital
Novaerus reduces environmental surface MRSA by 97% and reduces environmental surface TVC and environmental air MRSA at the Royal Free Hospital, London.
Evaluation of the Novaerus Technology in Intensive Care
Novaerus plasma technology shown to significantly reduce number of microorganisms at Brothers Hospitallers of Saint John of God Hospital in Łódź, Poland.
Evaluation of the Novaerus Technology in a Cardiology Clinic
Novaerus NV800 reduced airborne aerosols to non-detectable levels during a stress testing in a Cardiology Clinic
Evaluation of the Novaerus Technology in an Infectious Disease Hospital
Novaerus shown to reduce airborne bacteria and fungi 96% at the “Dr V. Babes” Hospital of Infectious and Tropical Diseases in Bucharest, Romania.
Evaluation of the Novaerus Technology in an Emergency Hospital
Novaerus shown to reduce airborne Staphylococcus by 100%, airborne bacteria by 89% and airborne fungi by 87%.